573 related articles for article (PubMed ID: 24362685)
1. Structure and function of respiratory syncytial virus surface glycoproteins.
McLellan JS; Ray WC; Peeples ME
Curr Top Microbiol Immunol; 2013; 372():83-104. PubMed ID: 24362685
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
3. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
[TBL] [Abstract][Full Text] [Related]
4. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
5. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
7. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
[TBL] [Abstract][Full Text] [Related]
8. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
9. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.
Isaacs A; Cheung STM; Thakur N; Jaberolansar N; Young A; Modhiran N; Bailey D; Graham SP; Young PR; Chappell KJ; Watterson D
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696372
[TBL] [Abstract][Full Text] [Related]
13. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.
Mok H; Lee S; Utley TJ; Shepherd BE; Polosukhin VV; Collier ML; Davis NL; Johnston RE; Crowe JE
J Virol; 2007 Dec; 81(24):13710-22. PubMed ID: 17928349
[TBL] [Abstract][Full Text] [Related]
14. The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.
McGinnes Cullen L; Luo B; Wen Z; Zhang L; Durr E; Morrison TG
J Virol; 2023 Jan; 97(1):e0190022. PubMed ID: 36602367
[TBL] [Abstract][Full Text] [Related]
15. Clinical Potential of Prefusion RSV F-specific Antibodies.
Rossey I; McLellan JS; Saelens X; Schepens B
Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
McCool RS; Musayev M; Bush SM; Derrien-Colemyn A; Acreman CM; Wrapp D; Ruckwardt TJ; Graham BS; Mascola JR; McLellan JS
J Virol; 2023 Oct; 97(10):e0092923. PubMed ID: 37737588
[TBL] [Abstract][Full Text] [Related]
17. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
18. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
19. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
20. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
J Virol; 2017 May; 91(10):. PubMed ID: 28250126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
